STO · ALZCUR.ST
AlzeCure Pharma AB
SEK 6.50-SEK 0.02 (-0.31%)
AlzeCure Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 25.12% below the high.
Loading market information…
STO · MNTC.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Mentice AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Mentice AB (publ)’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -SEK 0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mentice AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -SEK 1.08-176.92% vs estimate | SEK 54.27M-40.36% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | SEK 0.08-63.64% vs estimate | SEK 86.22M-8.28% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -SEK 0.51-325.0% vs estimate | SEK 57.70M-40.21% vs estimate |
|---|
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 6.50-SEK 0.02 (-0.31%)
AlzeCure Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 25.12% below the high.
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
SEK 14.35+SEK 0.10 (+0.7%)
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
SEK 0.18-SEK 0.00 (-1.85%)
Acarix AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 47.69% below the high.
SEK 8.34-SEK 0.08 (-0.95%)
Integrum AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
SEK 12.60-SEK 0.30 (-2.33%)
Physitrack PLC’s quoted price sits in the upper half of its reported 52-week range, 22.94% below the high.
SEK 9.45SEK 0.00 (0.0%)
Promimic AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 51.41% below the high.
SEK 0.24+SEK 0.01 (+2.13%)
KDventures AB’s quoted price sits in the lower half of its reported 52-week range, 82.14% below the high.
